Desperate Hacker

Chapter 613 The enviable technology

America, Cancer Research Laboratory!

Since Wang Ziran came back last time, he has devoted all his energy to the management of the Cancer Research Foundation.

To be honest, her father has taken her by her side since she was a child, teaching her through words and deeds. At such an old age, compared with children born in ordinary families, Wang Ziran's financial intelligence is certainly not comparable to that of children from ordinary families!

At the beginning, Wang Ziran was not good at managing the funds of a cancer foundation.

Because she simply doesn’t understand these complex biology and cutting-edge medical technologies.

But as big names in some industries join in one after another.

The foundation's research finally began to make a series of breakthroughs.

And according to the suggestions given by the well-known experts she hired.

If possible, gene repair may be a good solution for Chen Qingfeng's disease.

But it stands to reason that Wang Ziran's lineup is not inferior.

Finally this new type of antibiotic was designed. Unimaginable experimental results were achieved.

Wang Ziran felt that maybe this road was blocked.

So after thinking about it, this plan has certainly become an optional plan.

It sounds a bit mysterious, but there is currently no reliable method in the world that can treat the lymphoma in Chen Qingfeng's body.

When Wang Ziran heard about this plan at first, he thought it was a bit ridiculous.

However, in the face of the success achieved by this computer team, in comparison, the entire team reached an unprecedented consensus, that is, they no longer rely on manpower, but rely on computers to break through the development of new drugs for rare lymphoma.

To put it simply, Chen Qingfeng suffered from cancer because he lacked a part of genetic information in his gene, which caused it to synthesize a wrong enzyme. It was this enzyme that caused the proliferation of cancer cells in his body.

As soon as the news came out, the medical community in the United States was instantly shocked!
However, Wang Ziran is not particularly happy about this, because so far, the cancer research center has not made any important progress in the cancer that Chen Qingfeng suffered from.

But the current question is how to modify the gene and whether it is possible to produce a protein that inhibits the growth of cancer cells. And use this as the basis for targeted drug research.

Treat cancer this way.

For such a long time, it was the Cancer Research Center in Lin'an that was the first to achieve results.

After this result was announced, the entire institute was stunned.

There are Nobel Prize-level scholars there.

Through the data input in the past, the computer actually designed a brand new protein. The biggest advantage of this protein is that it seems to be used as an unprecedented antibiotic.

But after the foundation's computer team announced their latest research results, it triggered a series of discussions in the industry.

……

But what he didn't expect was that the first to achieve the results was not a team of biologists, but a computer team that studied the use of generative AI for protein analysis.

Suddenly, top students who originally focused on molecular biology research came here to check out their new progress.

Because this new type of antibiotic can actually kill the most drug-resistant bacteria in history, Acinetobacter baumannii. And it has no effect on beneficial bacteria. At the same time, it is also extremely lethal to drug-resistant Staphylococcus aureus and Gram-negative bacteria.

Now there is another idea, which is to use normal cells to replace the incorrect genetic information in Chen Qingfeng's body.

However, Chen Qingfeng's huge investment could not be hidden from Wang Ziran, who had attended board meetings with his father since he was a child.

And now she has a new proposal, but it must get Chen Qingfeng's permission, that is, whether she can use new antibiotics to quickly realize cash, and then reinvest the obtained funds into the research and development of cancer drugs!

Research centers run by donations rely on the financial resources of donors, but if the donors' financial resources are exhausted in a short period of time, it will be difficult to maintain the research funds. Chen Qingfeng thought so too at first.

He does not want to directly rely on the research foundation to operate it himself.

But through generous donations.

But now both Chinese and American research foundations have given him good news.

Because the results they achieve may be directly realized.

……

Wang Ziran then got on the plane to Malaysia.

And then Yang Anni also learned the news.

She has worked in the pharmaceutical industry for so many years, so of course she knows what level of achievements Chen Qingfeng's two cancer research funds have achieved?
But it is a pity that the pharmaceutical industry will not allow this cutting-edge technology to be available so quickly.

The reason is simple, because it will infringe on the interests of existing medical interest groups.

Imagine once a new antibiotic comes out and passes Phase 3 clinical trials.

It has directly become a drug that can be used clinically. So how can the new drugs that pharmaceutical companies have spent great efforts to develop in recent years recover their costs?

Think about it from the perspective of Princeton Pharmaceuticals Group.

Chen Qingfeng continues to invest money in research and development on the side effects of flotaxin, which is a good thing for Princeton Pharmaceuticals.

Because once it succeeds, the results will be achieved on the basis of Princeton Pharma’s previous investment.

This is equivalent to someone spending money to help Princeton Pharmaceuticals solve the problems of the drugs it produces.

But if the direction of research deviates from this angle, it will be a threat to Princeton's pharmaceuticals.

Once more advanced, safer, and more effective anti-cancer drugs come out, if they no longer use Princeton Pharmaceuticals’ key patents, it means that the more than 60 billion US dollars in R&D funds invested over the years will be wasted in an instant.

But then again.

Anne Yang is just an executive at Princeton Pharmaceuticals.

The company's interests are only related to her salary.

But if a disruptive technology does come out, why can't she get involved?

So this time Yang Anni stayed put.

She even had the idea of ​​​​seeing the effects of Chen Qingfeng's new technology experiments.

Yang Anni pretended not to know, but through her own connections, she successively confirmed the achievements of the two cancer research foundations from Chinese academic circles and American academic circles.

The news from China was the work of Nobuyuki Yamanaka, which frightened pharmaceutical manufacturers. Not only Chinese manufacturers hated him, but Japanese pharmaceutical companies also hated him, as well as those foreign pharmaceutical companies investing in the country.

Because the achievements of Professor Shandong threaten their annual profits of hundreds of billions from insulin and hypoglycemic drugs.

The same is true here in the United States.

Chen Qingfeng's research institute, if we look at the process of developing antibiotics this time.

R&D costs are only one-twentieth to one-thirtieth of traditional R&D funding.

This new technology has simply made pharmaceutical giants around the world red-eyed!
(End of this chapter)